疫苗佐剂市场规模、份额和成长分析（按产品、佐剂类型、给药途径、疾病类型、应用、疫苗类型和地区）- 2025-2032 年产业预测

2023 年全球疫苗佐剂市场规模为 6.701 亿美元，预计将从 2024 年的 7.1171 亿美元成长到 2032 年的 11.5247 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.21%。

由于感染疾病的上升，包括新出现和重新出现的病原体，疫苗佐剂市场正在经历显着的增长。感染疾病的激增增加了对有效疫苗的需求，而佐剂是提高疫苗有效性的关键成分。随着全球对预防性医疗保健的关注，尤其是自 COVID-19 以来，人们更加重视疫苗接种作为预防疾病的关键策略。佐剂透过延长抗原在註射部位存在的时间、活化免疫细胞和调节免疫反应发挥至关重要的作用，最终产生更强、更持久的免疫力。随着研发带来针对多种疾病的创新疫苗，疫苗佐剂市场将继续扩大并提供丰富的成长机会。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析

疫苗佐剂市场规模（依产品划分）

• 市场概况
• 乳化助剂
• 皂素类佐剂
• 微粒佐剂
• 其他佐剂

疫苗佐剂市场规模（以佐剂类型）

• 市场概况
• 有机佐剂
• 无机佐剂

依给药途径分類的疫苗佐剂市场规模

• 市场概况
• 肌肉注射
• 皮下
• 其他给药途径

疫苗佐剂市场规模（依疾病类型）

• 市场概况
• 感染疾病
• 癌症
• 其他疾病

疫苗佐剂市场规模（依应用）

• 市场概况
• 调查应用
• 商业应用

疫苗佐剂市场规模（以疫苗类型划分）

• 市场概况
• 人类疫苗
  • 感染疾病
  • 治疗
• 兽医疫苗
  • 宠物
  • 家畜
• 其他动物

疫苗佐剂市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• GSK plc（UK）
• SEPPIC（France）
• Croda International Plc（UK）
• SPI Pharma（USA）
• Agenus Inc.（USA）
• Phibro Animal Health Corporation（USA）
• Aurorium（USA）
• Dynavax Technologies Corporation（USA）
• Novavax Inc.（USA）
• Merck KGaA（Germany）
• Vaxine Pty Ltd.（Australia）
• Hawaii Biotech Inc.（USA）
• CSL Limited（Australia）
• OZ Biosciences（France）
• InvivoGen（USA）
• Allergy Therapeutics（UK）
• EuBiologics Co., Ltd.（South Korea）
• Pacific GeneTech Limited（USA）
• Riboxx GmbH（Germany）
• Oncovir, Inc.（USA）

结论和建议

Global Vaccine Adjuvants Market size was valued at USD 670.1 million in 2023 and is poised to grow from USD 711.71 million in 2024 to USD 1152.47 million by 2032, growing at a CAGR of 6.21% during the forecast period (2025-2032).

The vaccine adjuvants market is experiencing significant growth driven by the rising incidence of infectious diseases, including both newly emerging and reemerging pathogens. This surge in infectious diseases has heightened the demand for effective vaccinations, positioning adjuvants as critical components in enhancing immunization efficacy. With a global focus on preventive healthcare, particularly post-COVID-19, there is an increasing emphasis on immunization as a primary strategy for disease prevention. Adjuvants play a pivotal role by prolonging antigen presence at the injection site, activating immune cells, and modulating the immune response, which ultimately fosters a stronger and more sustained immunity. As research and development yield innovative vaccines targeting diverse diseases, the market for vaccine adjuvants is poised for continued expansion, presenting abundant opportunities for growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segments Analysis

Global Vaccine Adjuvants Market is segmented by Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type and region. Based on Product, the market is segmented into Emulsion Adjuvants, Pathogen Components, Saponin-Based Adjuvants, Particulate-Based Adjuvants and Other Adjuvants. Based on Adjuvant Type, the market is segmented into Organic Adjuvants and Inorganic Adjuvants. Based on Route Of Administration, the market is segmented into Intramuscular, Subcutaneous and Other Routes of Administration. Based on Disease Type, the market is segmented into Infectious Diseases, Cancer and Other Diseases. Based on Application, the market is segmented into Research Applications and Commercial Applications. Based on Vaccine Type, the market is segmented into Human Vaccines, Veterinary Vaccines and Other Animals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Adjuvants Market

The COVID-19 pandemic has heightened global health concerns, leading to a significant rise in the demand for vaccinations, particularly those incorporating adjuvants. This trend is driven by the necessity for more effective vaccination strategies to combat a variety of infectious diseases and new emerging pathogens, which are crucial for maintaining community immunity. Consequently, vaccine manufacturers are actively seeking innovative methods to boost the potency of their vaccinations, investing in cutting-edge adjuvant technologies to enhance their effectiveness. This ongoing pursuit for improved vaccination solutions is a key driver in the Global Vaccine Adjuvants market.

Restraints in the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market faces significant constraints due to stringent regulatory barriers that impact the licensing of these products. These strict regulations can lead to delays in the market entry of new adjuvants, ultimately increasing costs for manufacturers and creating additional challenges for business growth. Navigating the complex regulatory landscape often requires substantial resources, making it particularly difficult for smaller companies to comply with safety standards and establish a foothold in the market. This regulatory burden poses a notable hurdle, potentially stifling innovation and competition in the vaccine adjuvant sector.

Market Trends of the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market is witnessing a significant trend towards personalized immunization plans, marking a transformative shift in vaccination strategies. As researchers increasingly focus on tailoring vaccines to individual patient profiles-considering genetic variations and specific immune responses-this approach aims to enhance vaccine efficacy and patient outcomes. By employing targeted adjuvants designed for diverse patient populations, the market is expected to drive innovation and demand for customized solutions. This evolution reflects a broader trend of precision medicine in immunization, indicating a growing commitment to improving public health through more effective and personalized vaccination strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Vaccine Adjuvants Market Size by Product & CAGR (2025-2032)

• Market Overview
• Emulsion Adjuvants
• Saponin-Based Adjuvants
• Particulate-Based Adjuvants
• Other Adjuvants

Global Vaccine Adjuvants Market Size by Adjuvant Type & CAGR (2025-2032)

• Market Overview
• Organic Adjuvants
• Inorganic Adjuvants
• Global Vaccine Adjuvants Market Size by Route Of Administration & CAGR (2025-2032)
• Market Overview
• Intramuscular
• Subcutaneous
• Other Routes of Administration

Global Vaccine Adjuvants Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Infectious Diseases
• Cancer
• Other Diseases

Global Vaccine Adjuvants Market Size by Application & CAGR (2025-2032)

• Market Overview
• Research Applications
• Commercial Applications

Global Vaccine Adjuvants Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Human Vaccines
  • Infectious Diseases
  • Therapeutic
• Veterinary Vaccines
  • Companion Animals
  • Livestock Animals
• Other Animals

Global Vaccine Adjuvants Market Size & CAGR (2025-2032)

• North America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • US
  • Canada
• Europe (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SEPPIC (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Croda International Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SPI Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Phibro Animal Health Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurorium (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxine Pty Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hawaii Biotech Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OZ Biosciences (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InvivoGen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergy Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EuBiologics Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific GeneTech Limited (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Riboxx GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncovir, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations